MaxCyte, Inc. Filing of Form 10-Q

RNS Number : 5010N

MaxCyte, Inc.

08 May 2024

 

 

 

MaxCyte announces filing of Form 10-Q for the quarterly period ended March 31, 2024

 

ROCKVILLE, MD, May 8, 2024 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, announced that it has filed a Form 10-Q with the SEC for the quarterly period ended March 31, 2024. The Company has also filed a Form 8-K with the SEC related to updates to the information contained in their corporate deck.

 

A copy of the Form 10-Q and Form 8-K are available to view on the SEC's website at www.sec.gov and have also been posted to the "SEC filings" page of the Company's website, https://investors.maxcyte.com/.

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn.

 

MaxCyte Contacts:

 

US IR Adviser  Gilmartin Group  David Deuchler, CFA	[phone]  [e-mail]
Nominated Adviser and Joint Corporate Broker  Panmure Gordon  Emma Earl / Freddy Crossley  Corporate Broking  Rupert Dearden	[phone]
UK IR Adviser ICR Consilium Mary-Jane Elliott Chris Welsh	[phone] [e-mail]

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCQKOBKOBKDFPK